Research Focus
The Molecular Immunology Laboratory works on the immunology of infectious diseases such as malaria, as well as cancer and autoimmunity. In 2016, the laboratory discovered programmed cell death1 ligand 2 (PD-L2) was contrary to dogma, not a “brake” on the immune system, but actually an essential activator of immunity.
In 2023, the laboratory spun-out Fovero Therapeutics to develop novel immunotherapies for cancer and autoimmunity as well as diagnostics for these diseases. Fovero Therapeutics is focused on developing immunotherapies for cancers with the greatest unmet need such as MSS+ colon cancer and triple negative breast cancer.
Gallery
Research Projects
Current Research Projects
Development of a novel biologic immunotherapy for cancer
Further development of an antibody immunotherapy for cancer
Development of a novel immunotherapy for autoimmunity
Commercial involvement
Research Team
Ji Liu
Deshapriya Karunarathne
Bryan Lye
Funding
- US Department of Defence
- Therapeutic Innovation Australia
- National Health and Medical Research Council
- The University of Queensland
- QIMR Berghofer
- Brandon Biocatalyst
Further Information
- Associate Professor Melissa Eastgate RBWH
- Associate Professor Prof Brett Hughes RBWH
- Associate Professor Zarnie Lwin, RBWH
- Dr Michelle Nottage, RBWH
- Professor Maher Gandhi, Translation Research Institute